

STN

125197

Product

Sipuleucel T

Part D Page 1

Part D – Clinical (Pharmacology, Efficacy, Safety, and Statistical) Reviewers

CTD Module 2 Contents	Present?	If not, justification, action & status
Overall CTD Table of Contents [2.1]	<input checked="" type="radio"/> Y <input type="radio"/> N	
Introduction to the summary documents (1 page) [2.2]	<input checked="" type="radio"/> Y <input type="radio"/> N	
Clinical overview [2.5]	<input checked="" type="radio"/> Y <input type="radio"/> N	
Clinical summary [2.7] (summary of individual studies; comparison and analyses across studies)	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> Biopharmaceutics and associated analytical methods	Y <input checked="" type="radio"/> N	→ Not applicable
<input type="checkbox"/> Clinical pharmacology [includes immunogenicity]	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> Clinical Efficacy [for each indication]	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> Clinical Safety	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> Synopses of individual studies	<input checked="" type="radio"/> Y <input type="radio"/> N	

CTD Module 5 Contents	Present?	If not, justification, action & status
Module Table of Contents [5.1]	<input checked="" type="radio"/> Y <input type="radio"/> N	
Tabular Listing of all clinical studies [5.2]	<input checked="" type="radio"/> Y <input type="radio"/> N	
Study Reports and related information [5.3]	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> Biopharmaceutic	<input checked="" type="radio"/> Y <input type="radio"/> N	→ Not applicable
<input type="checkbox"/> Studies pertinent to Pharmacokinetics using Human Biomaterials	Y <input checked="" type="radio"/> N	
<input type="checkbox"/> Pharmacokinetics (PK)	Y <input checked="" type="radio"/> N	} Not applicable
<input type="checkbox"/> Pharmacodynamic (PD)	Y <input checked="" type="radio"/> N	
<input type="checkbox"/> Efficacy and Safety	<input checked="" type="radio"/> Y <input type="radio"/> N	→ product has not been approved
<input type="checkbox"/> Postmarketing experience	Y <input checked="" type="radio"/> N	
<input type="checkbox"/> Case report forms	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> Individual patient listings (indexed by study)	<input checked="" type="radio"/> Y <input type="radio"/> N	
o electronic datasets (e.g. SAS)	<input checked="" type="radio"/> Y <input type="radio"/> N	
Literature references and copies [5.4]	<input checked="" type="radio"/> Y <input type="radio"/> N	

Examples of Filing Issues	Yes?	If not, action & status
Content, presentation, and organization sufficient to permit substantive review?	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> legible	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> English (or certified translation into English)	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> compatible file formats	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> navigable hyper-links	<input checked="" type="radio"/> Y <input type="radio"/> N	
<input type="checkbox"/> interpretable data tabulations (line listings) & graphical displays	<input checked="" type="radio"/> Y <input type="radio"/> N	

STN 125197

Product

Sipuleucel T

Part D Page 2

Examples of Filing Issues	Yes?	If not, action & status
<input type="checkbox"/> summary reports reference the location of individual data and records	(Y) N	
<input type="checkbox"/> protocols for clinical trials present	(Y) N	
<input type="checkbox"/> all electronic submission components usable	(Y) N	
statement for each clinical investigation:		
<input type="checkbox"/> conducted in compliance with IRB requirements	(Y) N	
<input type="checkbox"/> conducted in compliance with requirements for informed consent	(Y) N	
adequate and well-controlled clinical study data (e.g. not obviously inappropriate or clinically irrelevant study design or endpoints for efficacy)	(Y) N	
adequate explanation of why results from what appears to be a single controlled trial (or alternate method for demonstrating efficacy) should be accepted as scientifically valid without replication	(Y) N	
study design not clearly inappropriate (as reflected in regulations, well-established agency interpretation or correspondence) for the particular claim	(Y) N	
study(ies) assess the contribution of each component of a combination product [21 CFR 610.17]	Y (N)	Not applicable
total patient exposure (numbers or duration) at relevant doses is not clearly inadequate to evaluate safety (per standards communicated during IND review, or ICH or other guidance documents)	(Y) N	
adequate data to demonstrate safety and/or effectiveness in the population intended for use of the biological product based on age, gender, race, physiologic status, or concomitant therapy	(Y) N	
drug interaction studies communicated as during IND review as necessary are included	Y (N)	Not applicable
assessed drug effects whose assessment is required by well established agency interpretation or communicated during IND review	(Y) N	
comprehensive analysis of safety data from all current world-wide knowledge of product	(Y) N	

STN 125197

Product

Sipuleucel T

Part D Page 3

Examples of Filing Issues	Yes?	If not, action & status
data supporting the proposed dose and dose interval	(Y) N	
appropriate (e.g. protocol-specified) and complete statistical analyses of efficacy data	(Y) N	
adequate characterization of product specificity or mode of action	Y N	
data demonstrating comparability of product to be marketed to that used in clinical trials when significant changes in manufacturing processes or facilities have occurred	Y (N)	Not applicable
inadequate efficacy and/or safety data on product to be marketed when different from product used in clinical studies which are the basis of safety and efficacy determinations	Y (N)	Not applicable
all information reasonably known to the applicant and relevant to the safety and efficacy described?	(Y) N	

List of Clinical Studies (protocol number)	Final study report submitted?	Financial disclosure or certification submitted?	SAS & other electronic datasets complete & usable?	BiMo sites identified?
D9901	(Y) N	(Y) N NR	(Y) N	(Y) N NR
D9902A	(Y) N	(Y) N NR	(Y) N	(Y) N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR
	Y N	Y N NR	Y N	Y N NR

Y= yes; N=no; NR=not required

STN 125197 Product Sipuleucel T

Part D Page 4

List any issue not addressed above which should be identified as a reason for not filing the BLA/BLS. Also provide additional details if above charts did not provide enough room (or attach separate memo).

none

Is clinical site(s) inspection (BiMo) needed?

Yes.

Is an Advisory Committee needed?

Yes.

Recommendation (circle one): File RTF

Reviewer: [Signature] / 12-18-06 Type (circle one): Clinical Clin/Pharm Statistical
(signature/ date)
Ke Liu, MD, PhD

Concurrence:

Branch Chief: _____ Division. Director: _____
(signature/ date) (signature/ date)